MedPath

Fecal Microbial Transplantation in Severe Alcoholic Hepatitis

Phase 3
Conditions
Alcoholic Hepatitis
Interventions
Biological: Fecal microbial transplantation
Registration Number
NCT04758806
Lead Sponsor
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Brief Summary

1. A subtype of Alcoholic hepatitis (AH), named severe alcoholic hepatitis (SAH) is associated with high short-term mortality (J Hepatol, 2019)

2. The only SAH treatment option - corticosteroids (CS) - are often contraindicated or ineffective (STOPAH Trial)

3. New treatment modalities for remaining patients are much needed

4. Fecal microbial transplantation (FMT) is one of the promising therapies

5. Investigators aimed to see if FMT improves survival in patients admitted with SAH, not responding to-, or non-eligible for CS.

Detailed Description

* FMT via upper GI tract is provided to CS non-responders (NR) or non-eligible (NE) adult patients hospitalized with SAH (determined by the Lille-model).

* Modified version of the Sarin FMT protocol is used with microbiota material procured from unrelated healthy donors.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • consenting, adult
  • severe form of acute alcoholic hepatitis (SAH)
  • non-responder to corticosteroids according to the Lille model
  • patients with SAH not eligible for corticosteroids based on their contraindications
Exclusion Criteria
  • active infection
  • presence of untreated large / high-risk / bleeding esophageal varices
  • too sick for any therapy / futility (chronic extrahepatic organ failures, no potential for recovery, etc)
  • malignancy except for hepatocellular carcinoma in Milan criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Fecal microbial transplantation from unrelated donorFecal microbial transplantationFecal microbial transplant procured (frozen if needed) from healthy unrelated donors is administered via upper GI tract; predefined single dose is repeated at five consecutive days
Primary Outcome Measures
NameTimeMethod
Mortality1 year

Overall mortality

Secondary Outcome Measures
NameTimeMethod
Acute on chronic liver failureIn-Hospital

Acute on chronic liver failure by European definition

Trial Locations

Locations (1)

F.D.Roosevelt Teaching Hospital

🇸🇰

Banska Bystrica, Slovakia

© Copyright 2025. All Rights Reserved by MedPath